Four years ago, a new weapon in the war on cancer made it to clinical trials accompanied by headlines and hope. Gleevec, a drug manufactured by Novartis, appeared to selectively turn off a specific cancer-causing protein like a light switch, stopping the progress of a severe form of leukemia in its tracks.